After a failed first attempt, Chelsea Therapeutics International Ltd. reported that Northera (droxidopa) hit the mark in a study of patients with neurogenic orthostatic hypotension (NOH), a drop in blood pressure when taking a standing position. (BioWorld Today)

Interim data from one of Johnson & Johnson's Phase III trials of abiraterone and prednisone for prostate cancer were shaping up so nicely that an independent data monitoring committee called for stopping the trial early and placing the placebo group on the active drug. (BioWorld Today)

Privately held Acceleron Pharma Inc. entered a potential $498 million deal with Basingstoke, UK-based Shire plc to develop drugs for rare muscle disorders, including its Phase II candidate for Duchenne's muscular dystrophy (DMD). (BioWorld Today)